ALGS

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Aligos Therapeutics Inc

NASDAQ | ALGS

7.92

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 18, 2025)

$43.20M

Market Cap

-

P/E Ratio

-13.54

EPS

$46.80

52 Week High

$3.76

52 Week Low

HEALTHCARE

Sector

ALGS Chart

Recent Chart
Price Action

ALGS Technicals

Tags:

ALGS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $3.9M
Total Revenue $3.9M
Cost Of Revenue $2.6M
Costof Goods And Services Sold $2.6M
Operating Income -$89M
Selling General And Administrative $23M
Research And Development $70M
Operating Expenses $93M
Investment Income Net -
Net Interest Income $4.4M
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.6M
Income Before Tax -$131M
Income Tax Expense $331K
Interest And Debt Expense -
Net Income From Continuing Operations -$131M
Comprehensive Income Net Of Tax -
Ebit -$89M
Ebitda -$87M
Net Income -$131M

Revenue & Profitability

Earnings Performance

ALGS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $70M
Total Current Assets $62M
Cash And Cash Equivalents At Carrying Value $37M
Cash And Short Term Investments $37M
Inventory -
Current Net Receivables -
Total Non Current Assets $8M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $20M
Other Current Assets $5.2M
Other Non Current Assets -
Total Liabilities $99M
Total Current Liabilities $22M
Current Accounts Payable $2.6M
Deferred Revenue -
Current Debt -
Short Term Debt $3.5M
Total Non Current Liabilities $79M
Capital Lease Obligations $8.4M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $8.4M
Other Current Liabilities $16M
Other Non Current Liabilities $46K
Total Shareholder Equity -$29M
Treasury Stock -
Retained Earnings -$618M
Common Stock $8K
Common Stock Shares Outstanding $6.3M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$81M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.6M
Capital Expenditures $130K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$18M
Cashflow From Financing $355K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$131M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $3.9M
Total Revenue $3.9M
Cost Of Revenue $2.6M
Costof Goods And Services Sold $2.6M
Operating Income -$89M
Selling General And Administrative $23M
Research And Development $70M
Operating Expenses $93M
Investment Income Net -
Net Interest Income $4.4M
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.6M
Income Before Tax -$131M
Income Tax Expense $331K
Interest And Debt Expense -
Net Income From Continuing Operations -$131M
Comprehensive Income Net Of Tax -
Ebit -$89M
Ebitda -$87M
Net Income -$131M

ALGS News

ALGS Profile

Aligos Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Aligos Therapeutics, Inc. (ALGS) is a dynamic clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for viral infections and liver diseases. Its extensive pipeline features candidates for chronic hepatitis B and liver fibrosis, underscoring the company's commitment to addressing critical unmet medical needs through advanced scientific approaches and strategic collaborations. Aligos's dedication to pioneering transformative healthcare solutions positions it as a compelling investment opportunity for institutional investors seeking growth in the biopharmaceutical sector.

LPTX
+368.57%
$2.05
CANF
+11.96%
$0.40
ASBP
+15.77%
$0.10
ONDS
+25.33%
$7.84
NVDA
-2.28%
$182.34
WTO
-8.00%
$0.02
PLUG
+8.67%
$2.26
LOBO
+33.33%
$0.52
CHR
+0.63%
$0.04
ASST
+7.69%
$1.12
OLMA
+136.38%
$20.14
CMND
-21.84%
$0.21
TSLA
-1.87%
$401.25
F
+1.20%
$13.03
ACHR
-5.83%
$7.42
VHAI
-25.00%
$0.00
AXDX
-61.36%
$0.03
SOFI
-2.95%
$26.24
QUBT
+7.30%
$12.34
BITF
+3.48%
$2.67
NIO
-1.80%
$5.97
DNN
-0.62%
$2.37
ETHD
-8.17%
$5.22
KVUE
-2.52%
$16.24
WBD
+3.21%
$23.47
ADAP
-15.14%
$0.05
PLTR
-1.58%
$171.25
MARA
+3.21%
$11.88
SNAP
+1.56%
$8.30
PFE
+1.52%
$25.46
WULF
+9.50%
$12.10
CAN
+20.75%
$1.03
INTC
-0.67%
$34.47
AMD
-4.25%
$230.29
CIFR
+1.60%
$14.58
AMZN
-3.62%
$224.44
BMNR
+4.84%
$32.45
RGTI
+4.13%
$25.71
NOK
+0.07%
$6.66
NFLX
+3.44%
$114.09
HPE
-1.50%
$20.91
T
+0.56%
$25.61
TLRY
0.00%
$1.03
AAL
+0.28%
$12.37
RMBL
+60.50%
$3.21
GOOGL
+0.45%
$286.32
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
RR
+3.84%
$3.24
IREN
+3.03%
$48.85
GPUS
+0.79%
$0.24
XPEV
-10.31%
$22.43
SRM
+53.27%
$10.30
RIG
+1.13%
$4.12
BURU
-5.38%
$0.20
MU
-5.55%
$228.50
CLF
+2.05%
$11.19
KXIN
+1.83%
$0.28
RIVN
+2.17%
$15.19
BYND
-2.40%
$1.01
RUBI
+1.27%
$0.17
PLTD
+1.72%
$7.08
LFS
+73.31%
$6.68
QS
+0.38%
$13.00
GRAB
+0.23%
$5.34
APLT
+4.99%
$0.29
HIMS
-3.78%
$35.58
CRWV
+0.78%
$75.92
EPSM
+91.54%
$2.72
BBD
-0.69%
$3.59
GOOG
-0.22%
$284.96
AAPL
+0.23%
$268.09
WLGS
-5.57%
$0.04
BTG
-0.62%
$3.96
ONFO
+9.98%
$0.93
BTE
+3.80%
$3.13
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
BAC
+0.35%
$51.66
QBTS
+0.39%
$22.92
SOUN
+2.49%
$11.71
IONZ
-5.35%
$4.77
CGTL
-11.32%
$0.71
BTBT
+5.64%
$2.42
CLSK
+1.88%
$10.81
DVLT
-6.16%
$1.75
HOOD
-0.76%
$115.08
ABEV
-0.39%
$2.54
EOSE
+3.69%
$13.48
BMNU
+9.37%
$8.57
RF
-0.49%
$24.18
SMR
+2.32%
$21.55
GLMD
+3.80%
$1.09
PLTZ
+3.52%
$7.35
AFMD
-34.94%
$0.18
FCX
+2.53%
$39.99
VALE
+0.28%
$12.20
MRK
+4.11%
$96.68
SMCI
+3.38%
$35.25
RXRX
+1.57%
$4.18
LPTX
+368.57%
$2.05
CANF
+11.96%
$0.40
ASBP
+15.77%
$0.10
ONDS
+25.33%
$7.84
NVDA
-2.28%
$182.34
WTO
-8.00%
$0.02
PLUG
+8.67%
$2.26
LOBO
+33.33%
$0.52
CHR
+0.63%
$0.04
ASST
+7.69%
$1.12
OLMA
+136.38%
$20.14
CMND
-21.84%
$0.21
TSLA
-1.87%
$401.25
F
+1.20%
$13.03
ACHR
-5.83%
$7.42
VHAI
-25.00%
$0.00
AXDX
-61.36%
$0.03
SOFI
-2.95%
$26.24
QUBT
+7.30%
$12.34
BITF
+3.48%
$2.67
NIO
-1.80%
$5.97
DNN
-0.62%
$2.37
ETHD
-8.17%
$5.22
KVUE
-2.52%
$16.24
WBD
+3.21%
$23.47
ADAP
-15.14%
$0.05
PLTR
-1.58%
$171.25
MARA
+3.21%
$11.88
SNAP
+1.56%
$8.30
PFE
+1.52%
$25.46
WULF
+9.50%
$12.10
CAN
+20.75%
$1.03
INTC
-0.67%
$34.47
AMD
-4.25%
$230.29
CIFR
+1.60%
$14.58
AMZN
-3.62%
$224.44
BMNR
+4.84%
$32.45
RGTI
+4.13%
$25.71
NOK
+0.07%
$6.66
NFLX
+3.44%
$114.09
HPE
-1.50%
$20.91
T
+0.56%
$25.61
TLRY
0.00%
$1.03
AAL
+0.28%
$12.37
RMBL
+60.50%
$3.21
GOOGL
+0.45%
$286.32
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
RR
+3.84%
$3.24
IREN
+3.03%
$48.85
GPUS
+0.79%
$0.24
XPEV
-10.31%
$22.43
SRM
+53.27%
$10.30
RIG
+1.13%
$4.12
BURU
-5.38%
$0.20
MU
-5.55%
$228.50
CLF
+2.05%
$11.19
KXIN
+1.83%
$0.28
RIVN
+2.17%
$15.19
BYND
-2.40%
$1.01
RUBI
+1.27%
$0.17
PLTD
+1.72%
$7.08
LFS
+73.31%
$6.68
QS
+0.38%
$13.00
GRAB
+0.23%
$5.34
APLT
+4.99%
$0.29
HIMS
-3.78%
$35.58
CRWV
+0.78%
$75.92
EPSM
+91.54%
$2.72
BBD
-0.69%
$3.59
GOOG
-0.22%
$284.96
AAPL
+0.23%
$268.09
WLGS
-5.57%
$0.04
BTG
-0.62%
$3.96
ONFO
+9.98%
$0.93
BTE
+3.80%
$3.13
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
BAC
+0.35%
$51.66
QBTS
+0.39%
$22.92
SOUN
+2.49%
$11.71
IONZ
-5.35%
$4.77
CGTL
-11.32%
$0.71
BTBT
+5.64%
$2.42
CLSK
+1.88%
$10.81
DVLT
-6.16%
$1.75
HOOD
-0.76%
$115.08
ABEV
-0.39%
$2.54
EOSE
+3.69%
$13.48
BMNU
+9.37%
$8.57
RF
-0.49%
$24.18
SMR
+2.32%
$21.55
GLMD
+3.80%
$1.09
PLTZ
+3.52%
$7.35
AFMD
-34.94%
$0.18
FCX
+2.53%
$39.99
VALE
+0.28%
$12.20
MRK
+4.11%
$96.68
SMCI
+3.38%
$35.25
RXRX
+1.57%
$4.18
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.